SuperworthHalozyme Therapeutics EPS HALO
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $3.35
- Latest quarter, Q2 FY26
- $1.90
- +43% on a year earlier
- Fiscal year 2025
- $2.49
- −27% on the year before
Halozyme Therapeutics' earnings per share was $3.35 over the twelve months to Jun 30, 2026, down 23% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.90, up 43% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 23% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.49 | −27% |
| FY2024 | $3.43 | +63% |
| FY2023 | $2.11 | +47% |
| FY2022 | $1.44 | −48% |
| FY2021 | $2.75 | +206% |
| FY2020 | $0.90 | n/a |
| FY2019 | −$0.50 | n/a |
| FY2018 | −$0.55 | n/a |
| FY2017 | n/a | n/a |
| FY2016 | n/a | n/a |
| FY2014 | −$0.55 | n/a |
| FY2013 | −$0.73 | n/a |
| FY2012 | −$0.49 | n/a |
| FY2011 | −$0.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.90 | +43% | $3.35 | |
| Q1 FY26 | $1.22 | +31% | $2.78 | |
| Q4 FY25 | −$1.20 | −213% | $2.49 | |
| Q3 FY25 | $1.43 | +36% | $4.75 | |
| Q2 FY25 | $1.33 | +85% | $4.37 | |
| Q1 FY25 | $0.93 | +55% | $3.76 | |
| Q4 FY24 | $1.06 | +63% | $3.43 | |
| Q3 FY24 | $1.05 | +72% | $3.02 | |
| Q2 FY24 | $0.72 | +29% | $2.58 | |
| Q1 FY24 | $0.60 | +107% | $2.42 | |
| Q4 FY23 | $0.65 | +59% | $2.11 | |
| Q3 FY23 | $0.61 | +39% | $1.87 |
Against its peers
Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ONCBeOne Medicines | $0.43 | |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| Peer median | $6.38 |
Where Halozyme Therapeutics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Halozyme Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.